(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

NCT02047604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: SAN-300 0.5 mg/kg QW
DRUG: SAN-300 1.0 mg/kg QW
DRUG: SAN-300 2.0 mg/kg QOW
DRUG: SAN-300 4.0 mg/kg QOW
DRUG: SAN-300 4.0 mg/kg QW
DRUG: Placebo

Sponsor

Bausch Health Americas, Inc.